Platelet Protection Using the Glycoprotein IIb/IIIa Inhibitor Tirofiban in a Patient With Heparin-Induced Thrombocytopenia Undergoing Aortic Valve Replacement Requiring Cardiopulmonary Bypass

Plastic Surgical Nursing

Volumn 2, Issue 2, 2003, Pages 119-124

  Guyer, Kirk E ^a   Carville, David G M ^a   Lau, Wei C ^b  

^a INDIANA UNIVERSITY SOUTH BEND   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Anti GPIIb IIIa agents; Heparin induced thrombocytopenia; Platelet protection

Indexed keywords

EID: 34548427205     PISSN: 07415206     EISSN: 15501841     Source Type: Journal    
DOI: 10.1097/00134384-200306000-00008     Document Type: Article

References (21)

1. Hass S, Walenga JM, Jeske WP, et al. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Haemost 1999; 25:67-75.
2. Laposata M, Green D, Van Cott EM, et al. College of American Pathologist Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122:799-807.
3. Koster A, Meyer O, Fischer TH, et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. J Thorac Cardiovasc Surg 2001; 122:1254-1255.
4. Slaughter TF, Greenberg CS. Heparin-associated thrombocytopenia and thrombosis: implications for perioperative management. Anesthesiology 1997; 87:667-675.
5. Poetzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000; 343:515.
6. Koster A. Management of heparin-induced thrombocytopenia type II in cardiac surgery. In:Heparin-Induced Thrombocytopenia in Cardiac Surgery: A Significant and Growing Problem. Satellite Symposia of the Society of Cardiovascular Anesthesiologists. April 2002.
7. Ogilby JD, Carville DGM. Anticoagulant management in interventional cardiology. Cardiovasc News Rep 1998; 19:34-47.
8. Koster A, Kukucka M, Friedhelm B, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001; 94:245-251.
9. Jeske WP, Walenga JM, Ahmad S, et al. Short-acting glycoprotein IIb-IIIa inhibitors may be safer for the management of patients with active heparin-induced thrombotic syndrome. Thromb Haemost 1999; 82(suppl):389.
10. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 95:809-813.
11. Lau WC, Walker CT, Ogilby D, et al. Evaluation of a near patient platelet function assay-performance and clinical utility. Ann Cardiac Anaesth 2002; 5:33-42.
12. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168:178-195.
13. Born GVR, Hardisty RM. Platelets. In: Biggs R, ed. Human Blood Coagulation Haemostasis and Thrombosis. 2nd ed. London: Blackwell Scientific Publications; 1976:168-201.
14. Storey RF, Wilcox RG, Hepinstall S. Differential effects of glycoprotein GPIIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation 1998; 98:1616-1621.
15. Podczasy JJ, Lee J, Vucenik I. Evaluation of whole-blood lumiaggregation. Clin Appl Thromb Hemost 1997; 3:190-195.
16. Dade PFA-100. Platelet function analyzer. Technical information. 1997.
17. Lakkis NM, George S, Thomas E, et al. Use of ICHOR-Plateletworks to assess platelet function in patients treated with GPIIb/IIIa inhibitors. Cathet Cardiovasc Intervent 2001; 53:346-351.
18. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107:32-37.
19. Muylle L, Wouters E, De Bock R, et al. Reactions to platelet transfusion: the effect of the storage time of the concentrate. Transfus Med 1992; 2:289-293.
20. Accumetrics. Ultegra Rapid Platelet Function Assay-TRAP [product insert]. San Diego, CA: Accumetrics, 2000.
21. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 2000; 12(suppl F):14F-19F.